QuantLogix ← INCY scorecard
📅 INCY Earnings Preview
Incyte Genomics Inc
Next report (est.)
11/18/2026
Countdown
72 days
EPS growth YoY
+251.2%
Revenue growth YoY
+59.0%
Implied vs actual — last 8 reports
ReportOptions impliedActual moveMarket was
07/28/2026 ±2.7% +9.3% under-priced
04/28/2026 ±2.4% +2.1% over-priced
10/28/2025 ±2.2% -1.5% over-priced
07/29/2025 ±1.9% +10.3% under-priced
04/29/2025 ±2.4% +1.5% over-priced
10/29/2024 ±1.6% +12.0% under-priced
07/30/2024 ±2.7% -1.2% over-priced
04/30/2024 ±2.1% -1.0% over-priced
Across these reports, options implied an average ±2.3% move vs an actual average of 4.9% — the stock stayed inside the implied band 63% of the time.
Fundamentals into the print
QuarterEPS (dil.)RevenueNet income
Q2 FY2026 $2.81 $1.7B $586M
Q1 FY2026 $1.47 $1.3B $303M
Q3 FY2025 $2.11 $1.4B $424M
Q2 FY2025 $2.04 $1.2B $405M
Analyst posture
Buy / Strong Buy
18
Hold
17
Sell
0
Stable: +1 net change 30d
Live 5-factor engine read: Strong Buy · 63/100 Full scorecard →
Get alerted before every INCY report — free Full live analysis
🤖 Pro runs a 10-agent AI debate on INCY before the print — 5 analysts, bull vs bear, a risk read, and a trader's verdict. See Pro →

Incyte Genomics Inc (INCY) reports in 72 days, with the next report estimated for 11/18/2026. Across the last 8 reports, options priced an average ±2.3% earnings move while the stock actually moved 4.9% on average — the market has been roughly fair on INCY's earnings risk. Fundamentals into the print: EPS up 251.2% year-over-year, revenue up 59.0%. QuantLogix's live 5-factor engine currently reads INCY as a strong buy at 63/100.

Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →